Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trial
read at Endpoints ↗Positive readoutPositive
Legend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti.
The data come from an investigator-initiated trial in China that enrolled 12 patients with lymphoma. The company presented the results on Tuesday.
The early readout is being viewed as a momentum boost for the in vivo CAR-T field, though detailed efficacy and safety outcomes were not disclosed in the brief report.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti”
read at Endpoints ↗93 words · retrieved Jun 2
comments(0)
5-min edit window · permanent after that